WO2020246584A1 - ペプチド核酸を基盤としたアジュバント - Google Patents

ペプチド核酸を基盤としたアジュバント Download PDF

Info

Publication number
WO2020246584A1
WO2020246584A1 PCT/JP2020/022293 JP2020022293W WO2020246584A1 WO 2020246584 A1 WO2020246584 A1 WO 2020246584A1 JP 2020022293 W JP2020022293 W JP 2020022293W WO 2020246584 A1 WO2020246584 A1 WO 2020246584A1
Authority
WO
WIPO (PCT)
Prior art keywords
adjuvant
nucleic acid
peptide
administration
peptide nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/022293
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
亮大郎 三股
明日美 神田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denka Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Co Ltd filed Critical Denka Co Ltd
Priority to JP2021524929A priority Critical patent/JP7602457B2/ja
Priority to AU2020288030A priority patent/AU2020288030A1/en
Priority to CN202080041821.3A priority patent/CN113939313B/zh
Priority to KR1020217039788A priority patent/KR20220017919A/ko
Priority to EP20817766.7A priority patent/EP3981426A4/en
Priority to US17/616,490 priority patent/US12016920B2/en
Publication of WO2020246584A1 publication Critical patent/WO2020246584A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a peptide nucleic acid modified from a cell membrane penetrating peptide having an immunostimulatory ability.
  • the acquired immune system has the ability to form an immune memory that can quickly cope with foreign substances that have been experienced once, after the second exposure.
  • Vaccines utilize this immune memory, and vaccination makes it possible to obtain immunity capable of neutralizing the pathogen before exposure to the pathogen.
  • Approved vaccines include subunit vaccines such as live attenuated vaccines, inactivated vaccines and purified recombinant proteins.
  • Live attenuated vaccines are highly effective vaccines, but they are infectious and therefore safe. It is difficult to secure, and there is a concern of unexpected side reactions.
  • inactivated vaccines and subunit vaccines are superior in terms of safety to live attenuated vaccines, but lack the ability to induce innate immunity because they have lost their infectivity, so the antigen alone is sufficient. Cannot give a good acquired immunity. Therefore, most of the approved inactivated vaccines and subunit vaccines are preparations in which an adjuvant having an immunostimulatory ability is added to an antigen. Therefore, in the development of highly safe vaccines, highly safe inactivated vaccines and subunit vaccine antigens should be used, but in order to obtain sufficient efficacy, the addition of an adjuvant having immunostimulatory ability is added. You will need it.
  • Adjuvants used in approved vaccines include aluminum salts and squalene-based emulsions, but few adjuvants are approved, and aluminum salts are known to promote IgE induction (Non-Patent Document 1). ..
  • the above-mentioned adjuvant is an adjuvant for injection and is difficult to combine with a mucosal vaccine.
  • peptide nucleic acid which is a modified nucleic acid obtained by converting the sugar phosphate skeleton of the nucleic acid into an N- (2-aminoethyl) glycine skeleton, has a high double-stranded forming ability and is not degraded by an in vivo nuclease. Therefore, it is expected to be applied as an antisense molecule and the like.
  • PNA cell penetrating peptide
  • Marichal T Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, Bureau F, Desmet CJ. DNA released from dying host 2011 Jul 17; 17 (8): 996-1002.
  • the present invention relates to providing an adjuvant useful for preparing a highly effective and highly safe vaccine and a vaccine composition containing the adjuvant.
  • CPP cell membrane-permeable peptide
  • TAT Trans-Activator of Transcription Protein
  • HIV Human Immunologicy Virus
  • the present invention relates to the following 1) to 6).
  • An adjuvant consisting of a peptide nucleic acid to which a cell membrane penetrating peptide is bound.
  • An adjuvant composition containing a peptide nucleic acid to which a cell membrane penetrating peptide is bound and a pharmaceutically acceptable carrier.
  • a vaccine composition containing the adjuvant and antigen of 1).
  • IgG antibody titer against A / Singapore / GP1908 / 2015 strain by subcutaneous administration IgG antibody titer against B / Maryland / 15/2015 strain on subcutaneous administration. Neutralizing antibody titer against A / Singapore / GP1908 / 2015 strain on Day 35 by subcutaneous administration.
  • IgG antibody titer against A / Singapore / GP1908 / 2015 strain by nasal administration IgG antibody titer against B / Maryland / 15/2015 strain in nasal administration.
  • the "peptide nucleic acid to which a cell membrane-permeable peptide is bound” means a molecule in which a peptide nucleic acid is bound to the N- or C-terminal of the cell membrane-permeable peptide, and in the present specification, Mitsumata-Immunostimulusory Peptide nucleic acid Also called (MIP).
  • the “cell-penetrating peptide (CPP)” refers to a peptide that, when coexisting with a cell, passes through the cell membrane and translocates into the cell.
  • CPP cell-penetrating peptide
  • Table 1 Peptide derived from TAT of HIV, Penetratin derived from Antennapedia of Drosophila, polyarginine, Transportan derived from neuropeptide galanine, Pep-1 derived from Nuclear Localization Signal (NLS) of SV40, antibacterial peptide. LL37, but not limited to them.
  • Preferred are TAT-derived peptides peptides consisting of the amino acid sequence shown in SEQ ID NO: 1).
  • a “peptide nucleic acid (PNA)” is a nucleic acid analog having a skeleton in which the sugar-phosphate skeleton of a nucleic acid is replaced with N- (2-aminoethyl) glycine, and a base is bound by a methylene carbonyl bond.
  • the base in the peptide nucleic acid used in the present invention may be any of adenine, guanine, thymine, cytosine and uracil, and the chain length is preferably 20 mer or less, which is preferable from the viewpoint of adjuvant activity. Is 3 to 12 mer, more preferably 3 to 10 mer.
  • the structure of the peptide nucleic acid of 3 to 12 mer is shown in the following formula (1).
  • Base may be the same or different, indicating adenine, guanine, thymine, cytosine or uracil, R indicating -COOH or -CONH 2 , and n indicating an integer of 1-10.
  • suitable peptide nucleic acids include, for example, 3 mer or 10 mer peptide nucleic acids having at least one guanine or cytosine as a base, 3 mer peptide nucleic acids (G3PNA) having 3 guanines as bases, and 3 bases. Examples thereof include a 3 mer peptide nucleic acid (C3PNA) having cytosine, and a 10 mer peptide nucleic acid (C10PNA) having 10 cytosines as a base.
  • the MIP of the present invention is applied to the N-terminal of a cell-penetrating peptide and the N-terminal of a peptide nucleic acid via a chemical method, for example, a cross-linking agent having N-hydroxysuccinimide ester at both ends. It can be manufactured by covalently bonding.
  • the peptide nucleic acid can be synthesized by using, for example, an Fmoc type PNA monomer unit or the like, and using a solid phase peptide synthesis method known in the art.
  • MIP As a suitable MIP used in the present invention, the following peptide consisting of 13 amino acids derived from TAT of HIV (SEQ ID NO: 1) is covalently bonded to G3PNA at its C-terminal and shared with MIP01 (formula (2)) and C10PNA.
  • SEQ ID NO: 1 the following peptide consisting of 13 amino acids derived from TAT of HIV (SEQ ID NO: 1) is covalently bonded to G3PNA at its C-terminal and shared with MIP01 (formula (2)) and C10PNA.
  • the combined MIP03 (formula (3)) can be mentioned.
  • MIP01 represented by the formula (2) an influenza antigen (split antigen)
  • an influenza antigen split antigen
  • the antibody titer in blood against the antigen is obtained. Is higher than in the MIP-free group.
  • the IgA titer of the mucosa also increases.
  • MIP03 represented by the formula (3) has activation of NF ⁇ B and high inducing ability of IL-1 ⁇ , it is highly possible that it promotes activation of the innate immune system, and MIP is innate immunity. It is considered to be an adjuvant having the ability to activate.
  • MIP has an adjuvant activity that enhances the ability to induce antibodies in blood or mucosa in either injection or transmucosal administration, so that MIP becomes an adjuvant and MIP is pharmaceutically acceptable.
  • the composition containing the carrier can be an adjuvant composition.
  • MIP can also be used to produce adjuvants or adjuvant compositions.
  • the "adjuvant” means a substance that increases the immune response to the antigen when the antigen is injected or transmucosally administered.
  • the “mucosa” refers to the inner wall of a vertebrate, particularly an external lumen organ such as a digestive organ, a respiratory organ, a genitourinary organ, and an eye. Therefore, the transmucosal administration includes, but is not limited to, oral administration, nasal administration (nasal administration), oral administration, intravaginal administration, upper respiratory tract administration, alveolar administration, eye drop administration, and the like.
  • the adjuvant or adjuvant composition of the present invention can be administered in combination with the antigen, and the administration may be simultaneous with the administration of the antigen or before or after the administration of the antigen.
  • the dose of the adjuvant or adjuvant composition of the present invention can be appropriately determined according to the administration subject, administration method, administration form, and type of antigen.
  • the adjuvant of the present invention can be combined with an antigen to form a vaccine composition.
  • the vaccine composition of the present invention can be prepared by mixing an antigen and MIP, and a pharmaceutically acceptable carrier can be appropriately added to prepare an appropriate formulation.
  • MIP may be in a chemically bound state with an antigen or other component, or may be present in a free molecular state.
  • the antigen examples include natural products purified from pathogens, or proteins or peptides artificially produced by methods such as gene recombination, and specifically, virions and incomplete viruses which are complete virus particles. Particles, viral structural proteins, viral non-structural proteins, whole cells of pathogens, proteins or glycoproteins derived from pathogens, defense antigens, neutralizing epitopes, etc., which are infectious and have lost infectivity. (Inactivated antigen) and is included.
  • the inactivated antigen is, for example, inactivated by physical (X-ray irradiation, UV irradiation, heat, ultrasonic) or chemical (formalin, beta-propiolactone, binary ethyleneimine, mercury, alcohol, chlorine) or the like. However, it is not limited to those that have been used.
  • the antigen derived from the pathogen is preferably an inactivated antigen derived from the virus or pathogen.
  • Viruses include, for example, measles virus, rut virus, mumps virus, poliovirus, rotavirus, norovirus, adenovirus, enterovirus, herpesvirus, varicella virus, severe acute respiratory infection syndrome (SARS) virus, human immunodeficiency virus (HIV). ), Human T-cell leukemia virus (HTLV-1), human papillomavirus, Japanese encephalitis virus, Westnile virus, yellow fever virus, dengue virus, decavirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, type E Hepatitis virus, RS virus, influenza virus and the like can be mentioned, and influenza virus is preferable.
  • pathogenic bacteria examples include Klebs-Löynia, Clostridium tetani, Bordetella pertussis, Meningococcus, Influenza b, Streptococcus pneumoniae, Vibrio cholerae, Mycobacterium tuberculosis, and periodontal disease bacteria.
  • Dosage forms of the vaccine composition include, for example, liquid preparations, suspensions, lyophilized preparations and the like.
  • the liquid agent include purified water and those dissolved in a buffer solution.
  • the suspending agent include those suspended in purified water, a buffer solution, etc. together with methyl cellulose, hydroxymethyl cellulose, polyvinyl viloridone, gelatin, casein and the like.
  • absorption promoters, surfactants, preservatives, stabilizers, moisture proofing agents, solubilizing agents and the like can be added to these preparations, if necessary.
  • the vaccine composition of the present invention may contain an adjuvant other than MIP as long as it does not impair the immunogenicity and safety of the vaccine.
  • the amount of the antigen contained in the vaccine composition of the present invention is not particularly limited as long as it is sufficient to induce a specific antibody response, and is appropriately set in consideration of the ratio with the MIP to be used in combination. be able to.
  • a split antigen of influenza virus when used as an antigen, it may be contained within the range of 1 to 60 ⁇ g HA (HA equivalent), which is a single dose, and 9 to 15 ⁇ g HA (HA equivalent) is more preferable.
  • the concentration is a value obtained by measuring the concentration of HA protein by a test method defined by WHO or national standards such as a unified radioimmunoassay test method.
  • the route of administration of the vaccine composition of the present invention is not particularly limited, and administration by injection (sublingual administration, intramuscular administration, intradermal administration, intravenous administration), oral administration, parenteral administration (for example, nasal administration, eye drop administration, etc.) It may be administered via vaginal administration, sublingual administration, or transdermal administration), and is administered, for example, by dropping, spraying, or spraying into the nasal cavity.
  • the administration target of the adjuvant composition or vaccine composition of the present invention includes humans and mammals other than humans, but humans are preferable.
  • mammals other than humans include mice, rats, hamsters, guinea pigs, rabbits, pigs, cows, goats, sheep, dogs, cats, rhesus monkeys, cynomolgus monkeys, orangutans, chimpanzees and the like.
  • CPP01 TAT-derived peptide (SEQ ID NO: 1)
  • MIP01 represented by the above formula (2)
  • MIP03 represented by the formula (3) as MIP was outsourced to Peptide Institute of Japan.
  • Example 1 Evaluation of adjuvant activity by subcutaneous administration of MIP01 A / H1N1 subtype (A / Singapore / GP1908 / 2015 strain) and B / Peptide strain (B / Maryland / 15/2016 strain) of influenza HA vaccine "Seiken"
  • the undiluted solution was a split antigen (SV), and each split antigen was mixed so that the amount of hemaglutinine of each strain was 1 ⁇ g per 0.3 mL, and 1 ⁇ g of a cell membrane-permeable peptide consisting of 13 amino acids derived from HIV TAT or MIP01 was added thereto.
  • SV split antigen
  • 0.3 mL of the administration solution (Table 2) prepared as described above was administered subcutaneously to the back of BALB / c mice (female, 5 weeks old) twice at 3-week intervals (5 animals in each group), and each administration was performed. Two weeks after that, all blood was collected. Serum is prepared by centrifuging the blood obtained from all blood samples, and the IgG (Total IgG) titer that specifically binds to the A / Singapore / GP1908 / 2015 strain and the B / Maryland / 15/2016 strain of the serum is determined. It was measured. In addition, the neutralizing antibody titer against the A / Singapore / GP1908 / 2015 strain was also measured in the serum after the second administration.
  • the IgG titers of each administration group are as shown in FIGS. 1A and 1B.
  • the antigen-specific IgG titer in blood for each strain was higher than that in the adjuvant-non-adjuvant group in both the 1-time and 2-dose administrations.
  • the antigen-specific IgG titer in blood was higher in both the 1st and 2nd doses in the MIP01-administered group than in the CPP01-administered group. ..
  • FIG. 2 shows the neutralizing antibody titer against the A / Singapore / GP1908 / 2015 strain after two administrations.
  • the neutralizing antibody titer was also the highest in the MIP01-administered group, followed by the non-adjuvant-added group and the lowest value. Was shown in the CPP01 administration group. Therefore, it was confirmed that administration of MIP01 improved not only the antigen-specific IgG titer in blood but also the neutralizing antibody titer important for virus elimination, and the structure in which the peptide nucleic acid was bound to the cell membrane penetrating peptide was MIP01. It was considered to be important for exerting the adjuvant activity of the virus.
  • Example 2 Evaluation of adjuvant activity in nasal administration of MIP01 Similar to Example 1, A / H1N1 subtype (A / Singapore / GP1908 / 2015 strain) and B / Victoria strain (B / Maryland /) of influenza HA vaccine "Seiken" Each stock solution of 15/2016 strain) was used as a split antigen, and each split antigen was mixed so that the amount of hemaglutinine of each strain was 1 ⁇ g per 10 ⁇ L, and CPP01 or MIP01 was added to 10 ⁇ g. In addition, as a control, an antigen-only administration solution to which no adjuvant was added was also prepared.
  • the administration solution (Table 3) prepared as described above was administered to the nasal cavity of BALB / c mice (female, 5 weeks old) twice at 3-week intervals (5 animals in each group). Two weeks after each administration, all blood was collected and serum was prepared by centrifugation. In addition, after blood was collected 2 weeks after the second administration, the inside of the nasal cavity was washed with 400 ⁇ L of D-PBS containing a protease inhibitor per individual, and this washing solution was collected as a nasal washing solution.
  • the results of IgG titers of each strain are as shown in FIGS. 3A and 3B, and the antigen-specific IgG titer in blood for each strain, whether nasally administered or once or twice.
  • the titer was higher than that in the non-adjuvant group.
  • the IgG titer for the B / Maryland / 15/2016 strain was confirmed to have a significant increase in antibody titer compared to the non-adjuvant group (Mann-Whitney U test, p ⁇ 0.05).
  • the IgA titer for each strain was the highest in the MIP01-administered group at any time of administration, followed by the lowest in the adjuvant-added group. It was a CPP01 administration group (Fig. 4A, Fig. 4B). Therefore, MIP obtained by modifying a cell-penetrating peptide into a peptide nucleic acid has adjuvant activity not only by injection but also by transmucosal administration, and transmucosal administration promotes IgA induction in mucosa in addition to IgG in blood. It is considered that.
  • Example 3 Innate immunity activating ability of MIP03 The innate immunity activating ability of MIP03 was evaluated in vitro.
  • MIP03 was added to 1 ⁇ 10 6 cells / mL Raw 264.7 Reporter Cell Line (Novus biologicals, NBP2-26261) to a final concentration of 10, 20, 40 and 80 ⁇ M, 5% CO 2 , 2 at 37 ° C. After culturing for 1 day, the culture solution was collected. The collected culture broth was centrifuged at 12,000 ⁇ g for 1 minute, and the supernatant of the culture solution was measured for alkaline phosphatase and cytokines.
  • SEAP Reporter Gene Assay luminescence (Cayman Chemical, 600260) was used for the measurement of alkaline phosphatase, and Bio-Plex Pro mouse cytokine GI23-Plex (Bio-Rad, M60009RDPDB03) was used for the measurement of cytokines.
  • a medium was added as a negative control (NC)
  • Imiquimod (0.02 ⁇ M), which is an agonist of Toll-like receptor 7, was added as a positive control in cytokine measurement, and the evaluation was made in comparison with these.
  • the measurement results of alkaline phosphatase are as shown in FIG. 5, and it was confirmed that the luminescence signal of alkaline phosphatase was improved depending on the concentration of MIP03 added. Therefore, it was found that MIP03 promotes the activation of NF ⁇ B, suggesting that it activates innate immunity.
  • the results of cytokine measurement are shown in FIGS. 6 to 9, and it was confirmed that IL-1 ⁇ and IL-1 ⁇ induction increased in a concentration-dependent manner of MIP03 (FIGS. 6 and 7), and IL-1 ⁇ in particular was compared with Imiquimod. However, very high induction was confirmed (Fig. 7).
  • the measurement result of IL-13 is shown in FIG. 8 and the measurement result of IFN- ⁇ is shown in FIG. 9. .
  • MIP03 promotes the activation of the innate immune system via C-type Rectin Receptor and Nod-Like Receptor.
  • MIP is an adjuvant having the ability to activate innate immunity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/JP2020/022293 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント Ceased WO2020246584A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2021524929A JP7602457B2 (ja) 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント
AU2020288030A AU2020288030A1 (en) 2019-06-06 2020-06-05 Adjuvant based on peptide nucleic acid
CN202080041821.3A CN113939313B (zh) 2019-06-06 2020-06-05 以肽核酸为基础的佐剂
KR1020217039788A KR20220017919A (ko) 2019-06-06 2020-06-05 펩티드 핵산을 기반으로 한 아쥬반트
EP20817766.7A EP3981426A4 (en) 2019-06-06 2020-06-05 ADJUVANTS BASED ON PEPTIDE NUCLEIC ACID
US17/616,490 US12016920B2 (en) 2019-06-06 2020-06-05 Adjuvant based on peptide nucleic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019106444 2019-06-06
JP2019-106444 2019-06-06

Publications (1)

Publication Number Publication Date
WO2020246584A1 true WO2020246584A1 (ja) 2020-12-10

Family

ID=73652763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/022293 Ceased WO2020246584A1 (ja) 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント

Country Status (8)

Country Link
US (1) US12016920B2 (https=)
EP (1) EP3981426A4 (https=)
JP (1) JP7602457B2 (https=)
KR (1) KR20220017919A (https=)
CN (1) CN113939313B (https=)
AU (1) AU2020288030A1 (https=)
TW (1) TW202112394A (https=)
WO (1) WO2020246584A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022215737A1 (ja) 2021-04-07 2022-10-13 デンカ株式会社 アジュバント活性増強剤及びアジュバント組成物
JP2023128573A (ja) * 2022-03-03 2023-09-14 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537102A (ja) * 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016515538A (ja) * 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
ZA200707967B (en) 2005-04-08 2008-11-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2009126933A2 (en) * 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
MX374090B (es) * 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US9902973B2 (en) * 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2018013924A1 (en) * 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537102A (ja) * 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
JP2016515538A (ja) * 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAE, H. D. ET AL.: "Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery", MOL. PHARMACEUTICS, vol. 13, no. 9, 2016, pages 3196 - 3205, XP055769361 *
MARICHAL TOHATA KBEDORET DMESNIL CSABATEL CKOBIYAMA KLEKEUX PCOBAN CAKIRA SISHII KJ: "DNA released from dying host cells mediates aluminum adjuvant activity", NAT MED., vol. 17, no. 8, 17 July 2011 (2011-07-17), pages 996 - 1002
TAKAYAMA NORIKO: "Activation of mucous immunity by transnasal administration of CpG-ODN using SPG-R8", DRUG DELIVERY SYSTEM, vol. 22, no. 3, 1 May 2007 (2007-05-01), JP, pages 395, XP009532647 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022215737A1 (ja) 2021-04-07 2022-10-13 デンカ株式会社 アジュバント活性増強剤及びアジュバント組成物
JP2023128573A (ja) * 2022-03-03 2023-09-14 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン

Also Published As

Publication number Publication date
JP7602457B2 (ja) 2024-12-18
TW202112394A (zh) 2021-04-01
AU2020288030A1 (en) 2022-01-06
KR20220017919A (ko) 2022-02-14
EP3981426A1 (en) 2022-04-13
EP3981426A4 (en) 2023-06-07
CN113939313B (zh) 2024-11-01
JPWO2020246584A1 (https=) 2020-12-10
US12016920B2 (en) 2024-06-25
CN113939313A (zh) 2022-01-14
US20230330221A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
Ross et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice
JP2024150687A (ja) アジュバントおよび該アジュバントを含むワクチン
EA027803B1 (ru) ИММУНОГЕННЫЕ СОЕДИНЕНИЯ, ВКЛЮЧАЮЩИЕ ПЕПТИД gp41 ВИЧ, СВЯЗАННЫЙ С БЕЛКОМ-НОСИТЕЛЕМ CRM197
WO2020246584A1 (ja) ペプチド核酸を基盤としたアジュバント
US20230149537A1 (en) Vaccines, adjuvants, and methods of generating an immune response
US9198965B2 (en) Peptide adjuvant for influenza vaccination
EP4181953A2 (en) Post-exposure vaccination against viral respiratory infections
US20240207395A1 (en) Adjuvant activity enhancer and adjuvant composition
JP5901084B2 (ja) ペプチドアジュバント
US20220184200A1 (en) Virus-like particles and uses thereof
US12552788B2 (en) IMDQ-PEG-CHOL adjuvant and uses thereof
US20240197865A1 (en) Compositions and methods for preventing rsv and piv3 infections
US20250186575A1 (en) Vaccine construct and uses thereof
JP2023091085A (ja) 粘膜アジュバント
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
US20240207394A1 (en) Toll-like receptor agonist-nanoparticle vaccine adjuvant
EP4370681A1 (en) Influenza virus-based isolated recombinant virus
OA21734A (en) Influenza virus-based isolated recombinant virus.
Dong et al. pter 4
Green The development and use of antigen-antibody-LTB (Ag-MAb-LTB) complexes as immunogens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20817766

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021524929

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020288030

Country of ref document: AU

Date of ref document: 20200605

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020817766

Country of ref document: EP

Effective date: 20220107

WWW Wipo information: withdrawn in national office

Ref document number: 1020217039788

Country of ref document: KR

Ref document number: 2020817766

Country of ref document: EP